Influenza Vaccines and Use of Influenza Antiviral Medications
Influenza Prevention and Control Recommendations
Published for the 2010-11 Influenza Season; Adapted for the 2011-12 Influenza Season
Administration of TIV to persons receiving influenza antivirals for treatment or chemoprophylaxis is acceptable. The effect on safety and effectiveness of LAIV coadministration with influenza antiviral medications has not been studied. However, because influenza antivirals reduce replication of influenza viruses, LAIV should not be administered until 48 hours after cessation of influenza antiviral therapy. If influenza antiviral medications are administered within 2 weeks after receipt of LAIV, the vaccine dose should be repeated 48 or more hours after the last dose of antiviral medication. Persons receiving antivirals within the period 2 days before to 14 days after vaccination with LAIV should be revaccinated at a later date with any approved vaccine formulation.
NOTE: For 2012-13 Influenza Prevention and Control Recommendations see “Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) – United States, 2012-13 Season,” MMWR 2012 Aug 17; 61(32):613-618.
For 2011-12 Influenza Prevention and Control Recommendations see “Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011,” MMWR 2011 Aug 26; 60(33):1128-1132.
For 2010-11 Influenza Prevention and Control Recommendations see “Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,” MMWR 2010 Aug 6; 59(RR08):1-62.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - cdcinfo@cdc.gov